Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Related news

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

View all latest news

Kiniksa

Kiniksa is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

KNSAKiniksa2026-06-26 09:45 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

KNSAKiniksa2026-06-26 09:45 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-26 09:45 EST

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

KNSAKiniksa2026-06-26 09:45 EST

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

KNSAKiniksa2026-06-26 09:45 EST

Kiniksa Pharmaceuticals Provides Corporate Update

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States